comparemela.com

Latest Breaking News On - Universal asset management - Page 1 : comparemela.com

REGENXBIO (NASDAQ:RGNX) Stock Price Down 5%

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report)’s stock price traded down 5% on Monday . The stock traded as low as $13.22 and last traded at $13.38. 322,961 shares were traded during trading, a decline of 48% from the average session volume of 622,212 shares. The stock had previously closed at $14.08. Analyst Ratings Changes […]

Savara (NASDAQ:SVRA) Shares Up 6 1%

Savara Inc (NASDAQ:SVRA – Get Free Report) shot up 6.1% on Monday . The company traded as high as $4.22 and last traded at $4.20. 271,525 shares traded hands during trading, a decline of 69% from the average session volume of 883,007 shares. The stock had previously closed at $3.96. Analysts Set New Price Targets […]

Hesai Group (NASDAQ:HSAI) Stock Price Up 6 6%

Shares of Hesai Group (NASDAQ:HSAI – Get Free Report) rose 6.6% on Monday . The company traded as high as $5.03 and last traded at $5.03. Approximately 364,273 shares traded hands during trading, a decline of 52% from the average daily volume of 760,711 shares. The stock had previously closed at $4.72. Hesai Group Price […]

Frazier Life Sciences Management L P Grows Stock Holdings in Mirum Pharmaceuticals, Inc (NASDAQ:MIRM)

Frazier Life Sciences Management L.P. lifted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 0.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,495,392 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Mirum Pharmaceuticals makes up about 10.3% of Frazier Life Sciences Management L.P.’s […]

Frazier Life Sciences Management L P Invests $15 76 Million in Dyne Therapeutics, Inc (NASDAQ:DYN)

Frazier Life Sciences Management L.P. bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,184,840 shares of the company’s stock, valued at approximately $15,758,000. Frazier Life Sciences Management L.P. owned 1.93% of Dyne Therapeutics at […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.